RecruitingPHASE1, PHASE2NCT06842173

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Studying Avian influenza

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Butantan Institute
Intervention: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg(biological)
Enrollment: 700 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2026

Study locations (5)

Centro de Terapias Avançadas E Inovadoras - Ct Terapias/Ufmg, Belo Horizonte, Minas Gerais, Brazil
Plátano Centro de Pesquisa Clínica LTDA, Recife, Pernambuco, Brazil
Fundação Faculdade Regional de Medicina de São Jose do Rio Preto - (Centro integrado de Pesquisa CIP), São José do Rio Preto, São Paulo, Brazil
Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preta da Universidade de São Paulo - (Centro de Pesquisa Clínica - S), Serrana, São Paulo, Brazil
Centro de Pesquisas Clínicas do Hospital das Clínicas da FMUSP, São Paulo, Brazil

Collaborators

Butantan Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06842173 on ClinicalTrials.gov

Other trials for Avian influenza

Additional recruiting or active studies for the same condition.

See all trials for Avian influenza →

← Back to all trials